Sanofi (SNYNF) Income towards Parent Company (2009 - 2026)
Sanofi (SNYNF) posted Income towards Parent Company of $1.9 billion for Q1 2026, up 124.55% sequentially from -$7.7 billion in Q4 2025, and down 4.04% YoY from $2.0 billion in Q1 2025.
Sanofi (SNYNF) Income towards Parent Company (2009 - 2026) Analysis & Trends
Sanofi (SNYNF) has 18 years of Income towards Parent Company data on file, last reported at $1.9 billion in Q1 2026.
- Quarterly Income towards Parent Company fell 4.04% year-over-year to $1.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.7 billion (up 28.41% YoY) and the FY2025 annual result came in at $9.1 billion, up 53.07% from the prior year.
- Income towards Parent Company advanced to $1.9 billion in Q1 2026 per SNYNF's latest filing, from -$7.7 billion in the prior quarter.
- The five-year high for Income towards Parent Company was $10.1 billion in Q3 2025, with the low at -$7.7 billion in Q4 2025.
- Average Income towards Parent Company over 5 years is $1.8 billion, with a median of $2.0 billion recorded in 2025.
- The widest YoY moves for Income towards Parent Company: up 272.1% in 2025, down 1543.62% in 2025.
- Sanofi's Income towards Parent Company stood at $3.2 billion in 2022, then tumbled by 118.81% to -$597.1 million in 2023, then surged by 189.3% to $533.2 million in 2024, then slumped by 1543.62% to -$7.7 billion in 2025, then surged by 124.55% to $1.9 billion in 2026.
- Business Quant data shows SNYNF's Income towards Parent Company at $1.9 billion in Q1 2026, -$7.7 billion in Q4 2025, and $10.1 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Sanofi | - | - | 9.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.89 Bn |
| Dec 31, 2025 | -7.70 Bn |
| Sep 30, 2025 | 10.07 Bn |
| Jun 30, 2025 | 4.46 Bn |
| Mar 31, 2025 | 1.97 Bn |
| Dec 31, 2024 | 533.23 Mn |
| Sep 30, 2024 | 3.09 Bn |
| Jun 30, 2024 | 1.20 Bn |
| Mar 31, 2024 | 1.23 Bn |
| Dec 31, 2023 | -597.15 Mn |
| Sep 30, 2023 | 2.75 Bn |
| Jun 30, 2023 | 1.56 Bn |
| Mar 31, 2023 | 2.14 Bn |
| Dec 31, 2022 | 3.17 Bn |
| Sep 30, 2022 | 2.09 Bn |
| Jun 30, 2022 | 1.25 Bn |
| Mar 31, 2022 | 2.25 Bn |
| Dec 31, 2021 | 1.29 Bn |
| Sep 30, 2021 | 2.72 Bn |
| Jun 30, 2021 | 1.44 Bn |